拉考沙胺聯合吡侖帕奈添加治療兒童難治性局灶性癲癇合并骨髓增生異常綜合征一例并文獻復習_Journal of Epilepsy

Authors：

 黃玲玲 ¹ , 吳正玉 ¹ , 劉程桃 ² , 孟麗萍 ¹ , 涂松濟 ¹ , 儲金華 ¹

1. ;
2. ;

Corresponding?author：

黃玲玲, Email: huanglingling803@sohu.com

Keywords：

拉考沙胺; 吡侖帕奈; 兒童; 局灶性癲癇; 骨髓增生異常綜合征

DOI：

10.7507/2096-0247.202406003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 黃玲玲, 吳正玉, 劉程桃, 孟麗萍, 涂松濟, 儲金華. 拉考沙胺聯合吡侖帕奈添加治療兒童難治性局灶性癲癇合并骨髓增生異常綜合征一例并文獻復習. Journal of Epilepsy, 2024, 10(5): 449-453. doi: 10.7507/2096-0247.202406003 Copy

1.	Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2.	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
3.	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
4.	McCune JS, Wang T, Bo-Subait K, et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyslophosphamide conditioning. Biol Blood Marrow Transplant, 2019, 25(7): 1424-1431.
5.	Adès L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. Br J Haematol, 2022, 198(3): 535-544.
6.	Fukuyama T, Tanaka M, Nakazawa Y, et al. Prophylactic treatment for hypertension and seizure in a case of allo-geneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplant, 2011, 15(8): E169-E173.
7.	唐靜, 劉清揚, 林京玉, 等. 丙戊酸相關血液系統不良反應嚴重程度的相關因素分析. 實用藥物與臨床2020, 23(5): 466-470.
8.	Danese E, Montagnana M, Favaloro EJ, et al. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost, 2020, 46(3): 264-274.
9.	梁棟, 羅莉, 程均祥. 左乙拉西坦不良反應分析. 中國藥物警訊, 2023, 20(9): 1054-1059.
10.	中華醫學會血液學分會. 骨髓增生異常綜合征中國診斷與治療指南(2019年版). 中華血液學雜志, 2019, 40(2): 89-97.
11.	Lin CY, Chang CW, Tseng WJ, et al. Therapeutic drug monitoring of perampanel: clinical utility and impact of co-medication on pharmacokinetic variability. Heliyon, 2024, 10(1): e23962.
12.	Yang C, Liu Z, Peng Y, et al. Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study. Front Pharmacol, 2023, 14: 1186786.
13.	Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016, 82(2): 422–430.
14.	De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res, 2016, 127: 93-100.
15.	陳國鋒, 李國銘, 柯鐘靈, 等. 吡侖帕奈在2~12歲兒童藥物難治性癲癇添加治療中的療效觀察. 中華實用兒科臨床雜志, 2022, 37(3): 182-185.
16.	Zhao T, Li HJ, Feng JR, et al. Efficacy, tolerability, and safety of treatment with Perampanel in Pediatric patients with epilepsy aged ≥4 years: a real-life observational study. Journal of Child Neurology, 2023, 38: 414-421.
17.	姜玉武, 王藝, 鐘建民, 等. 拉考沙胺添加治療在中國兒童局灶性癲癇發作中的安全性與有效性─一項全球多中心單臂研究期中分析. 中華實用兒科臨床雜志, 2023, 38(11): 850-856.
18.	Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolarebility of adjunctive Lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
19.	Mohammadi T, Nasiri J, Ghazavi MR, et al. Efficacy of Lacosamide add-on therapy on refractory focal epilepsies in children and adolesecnts: an open-label clinical trial. J Res Pharm Pract, 2022, 11(3): 109-115.
20.	Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – an open-label trial. Seizure. 2019, 71: 166–173.
21.	Farkas MK, Beller C, Bozorg A, et al. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2/3 trial. Epilepsia Open, 2023, 8(1): 146-153.
22.	Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
23.	肖瀟, 湯繼宏, 張兵兵, 等. 拉考沙胺及吡侖帕奈添加治療FIRES2例報告及文獻復習. 甘肅醫藥, 2023, 42(1): 91-93+96.

1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
3. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
4. McCune JS, Wang T, Bo-Subait K, et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyslophosphamide conditioning. Biol Blood Marrow Transplant, 2019, 25(7): 1424-1431.
5. Adès L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. Br J Haematol, 2022, 198(3): 535-544.
6. Fukuyama T, Tanaka M, Nakazawa Y, et al. Prophylactic treatment for hypertension and seizure in a case of allo-geneic hematopoietic stem cell transplantation after posterior reversible encephalopathy syndrome. Pediatr Transplant, 2011, 15(8): E169-E173.
7. 唐靜, 劉清揚, 林京玉, 等. 丙戊酸相關血液系統不良反應嚴重程度的相關因素分析. 實用藥物與臨床2020, 23(5): 466-470.
8. Danese E, Montagnana M, Favaloro EJ, et al. Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost, 2020, 46(3): 264-274.
9. 梁棟, 羅莉, 程均祥. 左乙拉西坦不良反應分析. 中國藥物警訊, 2023, 20(9): 1054-1059.
10. 中華醫學會血液學分會. 骨髓增生異常綜合征中國診斷與治療指南(2019年版). 中華血液學雜志, 2019, 40(2): 89-97.
11. Lin CY, Chang CW, Tseng WJ, et al. Therapeutic drug monitoring of perampanel: clinical utility and impact of co-medication on pharmacokinetic variability. Heliyon, 2024, 10(1): e23962.
12. Yang C, Liu Z, Peng Y, et al. Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: a real world study. Front Pharmacol, 2023, 14: 1186786.
13. Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016, 82(2): 422–430.
14. De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res, 2016, 127: 93-100.
15. 陳國鋒, 李國銘, 柯鐘靈, 等. 吡侖帕奈在2~12歲兒童藥物難治性癲癇添加治療中的療效觀察. 中華實用兒科臨床雜志, 2022, 37(3): 182-185.
16. Zhao T, Li HJ, Feng JR, et al. Efficacy, tolerability, and safety of treatment with Perampanel in Pediatric patients with epilepsy aged ≥4 years: a real-life observational study. Journal of Child Neurology, 2023, 38: 414-421.
17. 姜玉武, 王藝, 鐘建民, 等. 拉考沙胺添加治療在中國兒童局灶性癲癇發作中的安全性與有效性─一項全球多中心單臂研究期中分析. 中華實用兒科臨床雜志, 2023, 38(11): 850-856.
18. Farkas V, Steinborn B, Flamini JR, et al. Efficacy and tolarebility of adjunctive Lacosamide in pediatric patients with focal seizures. Neurology, 2019, 93(12): e1212-e1226.
19. Mohammadi T, Nasiri J, Ghazavi MR, et al. Efficacy of Lacosamide add-on therapy on refractory focal epilepsies in children and adolesecnts: an open-label clinical trial. J Res Pharm Pract, 2022, 11(3): 109-115.
20. Ferreira JA, Le Pichon JB, Abdelmoity AT, et al. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – an open-label trial. Seizure. 2019, 71: 166–173.
21. Farkas MK, Beller C, Bozorg A, et al. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2/3 trial. Epilepsia Open, 2023, 8(1): 146-153.
22. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs, 2022, 82(2): 199-218.
23. 肖瀟, 湯繼宏, 張兵兵, 等. 拉考沙胺及吡侖帕奈添加治療FIRES2例報告及文獻復習. 甘肅醫藥, 2023, 42(1): 91-93+96.

Previous Article
基于雨課堂的翻轉課堂模式在長程腦電圖教學實踐中的探索
Next Article
DPAGT1基因變異相關先天性糖基化障礙一例并文獻復習

Journal of Epilepsy

拉考沙胺聯合吡侖帕奈添加治療兒童難治性局灶性癲癇合并骨髓增生異常綜合征一例并文獻復習

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content